SSShivani Sachdev

Shivani Sachdev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shivani Sachdev has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Highly biased agonism for GPCR ligands via nanobody tethering

    by Shivani Sachdev, Brendan A. Creemer, Thomas J. Gardella, Ross W. Cheloha

    Ligand-induced activation of G protein-coupled receptors (GPCRs) can initiate signaling through multiple distinct pathways with differing biological and physiological outcomes. There is intense interest in understanding how variation in GPCR ligand structure can be used to promote pathway selective signaling (“biased agonism”) with the goal of promoting desirable responses and avoiding deleterious side effects. Here we present a new approach in which a conventional peptide ligand for the type 1 parathyroid hormone receptor (PTHR1) is converted from an agonist which induces signaling through all relevant pathways to a compound that is highly selective for a single pathway. This is achieved not through variation in the core structure of the agonist, but rather by linking it to a nanobody tethering agent that binds with high affinity to a separate site on the receptor not involved in signal transduction. The resulting conjugate represents the most biased agonist of PTHR1 reported to date. This approach holds promise for facile generation of pathway selective ligands for other GPCRs.

  • Open Access

    Differential activation of G protein‐mediated signaling by synthetic cannabinoid receptor agonists

    by Shivani Sachdev, Samuel D. Banister, Marina Santiago, Chris Bladen, Michael Kassiou, Mark Connor

    Synthetic cannabinoid receptor agonists (SCRAs) are new psychoactive substances associated with acute intoxication and even death. However, the molecular mechanisms through which SCRAs may exert their toxic effects remain unclear—including the potential differential activation of G protein subtypes by cannabinoid receptor type 1 (CB1), a major target of SCRA. We measured CB1‐mediated activation of Gαs and Gαi/o proteins by SCRAs by examining stimulation (pertussis toxin, PTX treated) as well as inhibition (non‐PTX treated) of forskolin (FSK)‐induced cyclic adenosine monophosphate (cAMP) accumulation in human embryonic kidney (HEK) cells stably expressing CB1. Real‐time measurements of stimulation and inhibition of cAMP levels were made using a BRET biosensor. We found that the maximum concentration of SCRAs tested (10 µmol L−1), increased cAMP levels 12%‐45% above that produced by FSK alone, while the phytocannabinoid THC did not significantly alter cAMP levels in PTX‐treated HEK‐CB1 cells. All SCRAs had greater potency to inhibit FSK‐induced cAMP levels than to stimulate cAMP levels. The rank order of potencies for SCRA stimulation of cAMP (Gαs) was PB‐22 > 5F‐MDMB‐PICA > JWH‐018 ≈ AB‐FUBINACA > XLR‐11. By contrast, the potency of SCRAs for inhibition of cAMP (Gαi/o) was 5F‐MDMB‐PICA > AB‐FUBINACA > PB‐22 > JWH‐018 > XLR‐11. The different rank order of potency and EMax of the SCRAs to stimulate Gαs‐like signaling compared to Gαi/o signaling suggests differences in G protein preference between SCRAs. Understanding the apparent differences among these drugs may contribute to unravelling their complex effects in humans.


  • Open Access

    Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells

    by Shivani Sachdev, Rochelle Boyd, Natasha L. Grimsey, Marina Santiago, Mark Connor

    Background Synthetic cannabinoids are a commonly used class of recreational drugs that can have significant adverse effects. There have been sporadic reports of co-consumption of illicit drugs with rodenticides such as warfarin and brodifacoum (BFC) over the past 20 years but recently, hundreds of people have been reported to have been poisoned with a mixture of synthetic cannabinoids and BFC. We have sought to establish whether BFC directly affects cannabinoid receptors, or their activation by the synthetic cannabinoid CP55940 or the phytocannabinoid Δ9-tetrahydrocannabinol (Δ9-THC). Methods The effects of BFC on the hyperpolarization of wild type AtT20 cells, or AtT20 cells stably expressing human CB1- or CB2- receptors, were studied using a fluorescent assay of membrane potential. The effect of BFC on CB1- and CB2-mediated inhibition of forskolin-stimulated adenylyl cyclase (AC) activation was measured using a BRET assay of cAMP levels in HEK 293 cells stably expressing human CB1 or CB2. Results BFC did not activate CB1 or CB2 receptors, or affect the hyperpolarization of wild type AtT20 cells produced by somatostatin. BFC (1 µM) did not affect the hyperpolarization of AtT20-CB1 or AtT20-CB2 cells produced by CP55940 or Δ9-THC. BFC (1 µM) did not affect the inhibition of forskolin-stimulated AC activity by CP55940 in HEK 293 cells expressing CB1 or CB2. BFC (1 µM) also failed to affect the desensitization of CB1 and CB2 signaling produced by prolonged (30 min) application of CP55940 or Δ9-THC to AtT20 cells. Discussion BFC is not a cannabinoid receptor agonist, and appeared not to affect cannabinoid receptor activation. Our data suggests there is no pharmacodynamic rationale for mixing BFC with synthetic cannabinoids; however, it does not speak to whether BFC may affect synthetic cannabinoid metabolism or biodistribution. The reasons underlying the mixing of BFC with synthetic cannabinoids are unknown, and it remains to be established whether the “contamination” was deliberate or accidental. However, the consequences for people who ingested the mixture were often serious, and sometimes fatal, but this seems unlikely to be due to BFC action at cannabinoid receptors.


  • Open Access

    Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ 9 -THC at Human CB 1 and CB 2 Receptors

    by Marina Santiago, Shivani Sachdev, Jonathon C. Arnold, Iain S. McGregor, Mark Connor

    Introduction: Compounds present in Cannabis sativa such as phytocannabinoids and terpenoids may act in concert to elicit therapeutic effects. Cannabinoids such as Δ 9 -tetrahydrocannabinol (Δ 9 -THC) directly activate cannabinoid receptor 1 (CB 1 ) and cannabinoid receptor 2 (CB 2 ); however, it is not known if terpenoids present in Cannabis also affect cannabinoid receptor signaling. Therefore, we examined six common terpenoids alone, and in combination with cannabinoid receptor agonists, on CB 1 and CB 2 signaling in vitro . Materials and Methods: Potassium channel activity in AtT20 FlpIn cells transfected with human CB 1 or CB 2 receptors was measured in real time using FLIPR ® membrane potential dye in a FlexStation 3 plate reader. Terpenoids were tested individually and in combination for periods up to 30 min. Endogenous somatostatin receptors served as a control for direct effects of drugs on potassium channels. Results: α-Pinene, β-pinene, β-caryophyllene, linalool, limonene, and β-myrcene (up to 30–100 μM) did not change membrane potential in AtT20 cells expressing CB 1 or CB 2 , or affect the response to a maximally effective concentration of the synthetic cannabinoid CP55,940. The presence of individual or a combination of terpenoids did not affect the hyperpolarization produced by Δ 9 -THC (10 μM): (CB 1 : control, 59%±7%; with terpenoids (10 μM each) 55%±4%; CB 2 : Δ 9 -THC 16%±5%, with terpenoids (10 μM each) 17%±4%). To investigate possible effect on desensitization of CB 1 responses, all six terpenoids were added together with Δ 9 -THC and signaling measured continuously over 30 min. Terpenoids did not affect desensitization, after 30 min the control hyperpolarization recovered by 63%±6% in the presence of the terpenoids recovery was 61%±5%. Discussion: None of the six of the most common terpenoids in Cannabis directly activated CB 1 or CB 2 , or modulated the signaling of the phytocannabinoid agonist Δ 9 -THC. These results suggest that if a phytocannabinoid–terpenoid entourage effect exists, it is not at the CB 1 or CB 2 receptor level. It remains possible that terpenoids activate CB 1 and CB 2 signaling pathways that do not involve potassium channels; however, it seems more likely that they may act at different molecular target(s) in the neuronal circuits important for the behavioral effect of Cannabis .


  • Open Access

    In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1receptors

    by Shivani Sachdev, Kiran Vemuri, Samuel D. Banister, Mitchell Longworth, Michael Kassiou, Marina Santiago, Alexandros Makriyannis, Mark Connor

    Background and Purpose: The morbidity and mortality associated with recreational use of synthetic cannabinoid receptor agonists (SCRAs) may reflect strong activation of CB1receptors and is a major health concern. The properties of SCRA at CB1receptors are not well defined. Here we have developed an assay to determine acute CB1receptor efficacy using receptor depletion with the irreversible CB1receptor antagonist AM6544, with application of the Black and Leff operational model to calculate efficacy.Experimental Approach: Receptor depletion in mouse AtT‐20 pituitary adenoma cells stably expressing human CB1receptors was achieved by pretreatment of cells with AM6544 (10 μM, 60 min). The CB1receptor‐mediated hyperpolarisation of AtT‐20 cells was measured using fluorescence‐based membrane potential dye. From data fit to the operational model, the efficacy (τ) and affinity (KA) parameters were obtained for each drug.Key Results: AM6544 did not affect the potency or maximal effect of native somatostatin receptor‐induced hyperpolarization. Theτvalue of ∆9‐THC was 80‐fold less than the reference CB receptor agonist CP55940 and 260‐fold less than the highest efficacy SCRA, 5F‐MDMB‐PICA. The operational efficacy of SCRAs ranged from 233 (5F‐MDMB‐PICA) to 28 (AB‐PINACA), with CP55940 in the middle of the efficacy rank order. There was no correlation between theτandKAvalues.Conclusions and Implications: All SCRAs tested showed substantially higher efficacy at CB1receptors than ∆9‐THC, which may contribute to the adverse effects seen with these drugs but not ∆9‐THC.


  • Open Access

    In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids

    by Shivani Sachdev, Kiran Vemuri, Samuel D. Banister, Mitchell Longworth, Michael Kassiou, Marina Santiago, Alexandros Makriyannis, Mark Connor

    BACKGROUND AND PURPOSE: The recreational use of synthetic cannabinoid receptor agonists (SCRA) new psychoactive substances is associated with significant morbidity and mortality compared with herbal cannabis. To explore the relationship between SCRA CB1 receptor activity and acute toxicity, we determined the CB1 efficacy of thirteen SCRAs using receptor depletion with the irreversible CB1 antagonist AM6544 followed by curve‐fitting with the Black and Leff operational model. We also investigated the effects of brodifacoum, an anticoagulant associated with a recent outbreak of SCRA poisoning, on the acute signalling of human CB1 receptors. EXPERIMENTAL APPROACH: Receptor depletion in mouse AtT‐20 pituitary adenoma cells stably expressing human CB1 was achieved by pre‐treatment of cells with AM6544 (10 μM, 60 mins). The CB1‐mediated hyperpolarisation of AtT‐20 cells was measured using fluorescence‐based membrane potential dye. The efficacy ( tau ) and affinity (K A ) parameters were obtained for each drug by fitting data to the operational model. We next determined the effect of brodifacoum (1 μM, 5 mins) on the hyperpolarization induced by subsequent application of CP55940 or Δ 9 ‐THC. KEY RESULTS: The tau value of Δ 9 ‐THC was 80‐fold less than the reference CB‐agonist CP55940, and 260‐fold less than the highest efficacy SCRA, 5F‐MDMB‐PICA. The operational efficacy of SCRAs ranged from 233 (5F‐MDMB‐PICA) to 28 (AB‐PINACA), with CP55940 in the middle of the efficacy rank order. Application of brodifacoum had no effect on the potency, or the maximal response produced by high efficacy cannabinoid CP55940 or low efficacy phytocannabinoid Δ 9 ‐THC (P9 ‐THC, which may contribute to the apparently greater toxicity of these drugs. Our data suggests that cannabinoid induced signaling was not affected by brodifacoum, indicating that combining SCRA with brodifacoum is not likely to enhance user experience through interactions with CB1. Support or Funding Information This work was supported by NHMRC Project Grant 1107088 awarded to M.K., and M.C. and National Institutes of Health grant P01DA009158 to A.M. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .


  • Open Access

    Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells

    by Shivani Sachdev, Rochelle Boyd, Natasha L Grimsey, Mark Connor

    Background: Synthetic cannabinoids are a commonly used class of recreational drugs that can have significant adverse effects. There have been sporadic reports of co-consumption of illicit drugs with rodenticides such as warfarin and brodifacoum (BFC) over the past 20 years but recently, hundreds of people have been reported to have been poisoned with a mixture of synthetic cannabinoids and BFC. We have sought to establish whether BFC directly affects cannabinoid receptors, or their activation by the synthetic cannabinoid CP55940 or the phytocannabinoid Δ 9 -tetrahydrocannabinol (Δ 9 -THC). Methods: The effects of BFC on the hyperpolarization of wild type AtT20 cells, or AtT20 cells stably expressing human CB 1 - and CB 2 -mediated receptors, were studied using a fluorescent assay of membrane potential. The effects of BFC on CB 1 and CB 2 mediated inhibition of forskolin-stimulated adenylyl cyclase (AC) activation was measured using a BRET assay of cAMP levels in HEK 293 cells stably expressing human CB 1 and CB 2 . Results: BFC did not activate CB 1 or CB 2 receptors, or affect the hyperpolarization of wild type AtT20 cells produced by somatostatin. BFC (10 µ M) did not affect the hyperpolarization of AtT20-CB 1 or AtT20-CB 2 cells produced by CP55940 or Δ 9 -THC. BFC (1 µ M) did not affect the inhibition of forskolin-stimulated AC activity by CP55940 in HEK 293 cells expressing CB 1 or CB 2 . BFC (1 µ M) also failed to affect the desensitization of CB 1 and CB 2 signalling produced by prolonged (30 min) application of CP55940 or Δ 9 -THC to AtT20 cells. Discussion: BFC is not a cannabinoid receptor agonist, and appeared not to affect cannabinoid receptor activation. Our data suggests there is no pharmacodynamic rationale for mixing BFC with synthetic cannabinoids, however, it does not speak to whether BFC may affect synthetic cannabinoid metabolism or biodistribution. The reasons underlying the mixing of BFC with synthetic cannabinoids are unknown, and it remains to be established whether the “contamination” was deliberate or accidental. However, the consequences for people who ingested the mixture were often serious, and sometimes fatal, but this seems unlikely to be due to BFC action at cannabinoid receptors.


  • Pharmacology of Valinate andtert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues

    by Samuel D. Banister, Mitchell Longworth, Richard Kevin, Shivani Sachdev, Marina Santiago, Jordyn Stuart, James B. C. Mack, Michelle Glass, Iain S. McGregor, Mark Connor, et al.

    Indole and indazole synthetic cannabinoids (SCs) featuring l-valinate or l-tert-leucinate pendant group have recently emerged as prevalent recreational drugs, and their use has been associated with serious adverse health effects. Due to the limited pharmacological data available for these compounds, 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues were synthesized and assessed for cannabimimetic activity in vitro and in vivo. All SCs acted as potent, highly efficacious agonists at CB1 (EC50 = 0.45–36 nM) and CB2 (EC50 = 4.6–128 nM) receptors in a fluorometric assay of membrane potential, with a general preference for CB1 activation. The cannabimimetic properties of two prevalent compounds with confirmed toxicity in humans, 5F-AMB and MDMB-FUBINACA, were demonstrated in vivo using biotelemetry in rats. Bradycardia and hypothermia were induced by 5F-AMB and MDMB-FUBINACA doses of 0.1–1 mg/kg (and 3 mg/kg for 5F-AMB), with MDMB-FUBINACA showing the most dramatic hypothermic response recorded in our laboratory for any SC (>3 °C at 0.3 mg/kg). Reversal of hypothermia by pretreatment with a CB1, but not CB2, antagonist was demonstrated for 5F-AMB and MDMB-FUBINACA, consistent with CB1-mediated effects in vivo. The in vitro and in vivo data indicate that these SCs act as highly efficacious CB receptor agonists with greater potency than Δ9-THC and earlier generations of SCs.